Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
about
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeClinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitisNuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults.Atezolizumab for the treatment of non-small cell lung cancer.Special topics in immunotherapy and radiation therapy: reirradiation and palliationIntegrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer.The safety of nivolumab for the treatment of advanced non-small cell lung cancer.The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.Nivolumab-induced Acute Fibrinous and Organizing Pneumonia (AFOP)Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis.Risk of pneumonitis with different immune checkpoint inhibitors in NSCLC.Do hospitals need oncological critical care units?Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505).Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis.T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors.Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.Implications of the tumor immune microenvironment for staging and therapeutics.Radiomics to predict immunotherapy-induced pneumonitis: proof of concept.Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy.Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.Hodgkin lymphoma: A review and update on recent progress.The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody.High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.Mogamulizumab for the treatment of T-cell lymphoma.Inhibitors of the PD-1 Pathway in Tumor Therapy.Multifunctional nanoparticles for cancer immunotherapy: A groundbreaking approach for reprogramming malfunctioned tumor environment.Decreased Survival After Combining Thoracic Irradiation and an Anti-PD-1 Antibody Correlated With Increased T-cell Infiltration Into Cardiac and Lung Tissues.Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care.Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report.
P2860
Q33793552-2BDE6F1A-064A-46C8-BCC1-B271FF496F6DQ33813378-1A3B586B-814D-47CD-93D6-92394A20CCE1Q37713503-8848A3FC-05EA-4C4A-A64A-68B7E60A8965Q38401891-4B281EBB-04C7-45A9-A66B-97E6AAB74A12Q38654099-F545C9D5-BE30-4B2F-90A5-6F6ED37810D8Q38675969-E314DD78-0EA6-4B6E-A4FE-6EACF1C0FEF0Q38771929-8AAD2D25-1C1F-45BC-8EE6-B7AD564FC135Q38771934-94C528B3-423B-4E23-9196-81E4E5E92276Q38788124-190B9599-143F-41CF-B4B8-98DA191F6534Q39227781-1A3ED046-5E96-48F9-B170-C30C6B73227FQ39430042-91DFA9E1-209D-4E5B-AD8B-C0514038D38BQ41356383-3CD0D998-4729-437F-99F8-E4899F484835Q41896400-AC3CAD26-D9C1-4DA7-B6AA-3B8C900D0BBFQ42264783-06272665-8C74-497B-950A-1716E5F0C84EQ42283210-3961B9BC-31E1-4635-B229-D6B07351E691Q42359063-9D672B40-9C04-4CB7-BF46-F2D8C546ED69Q42362328-FB903F8B-9F14-4D06-A7B7-C04BC12FEBF0Q42371658-C8B3149F-CB3F-4B83-BFA8-D4AAAEF2144FQ47102520-FE0CA0D3-6474-4A2C-AD0F-4B88308BB26AQ47126832-0D96A3CE-D812-49A9-A4A0-224BFD456EBAQ47131539-5C202326-0496-4C84-B41F-8902D608F09CQ47132997-82BC8F81-B48C-466F-85A8-CD211CD0030DQ47149194-7D7A0B1E-6424-4359-8660-61C2505A86E7Q47211203-E4623DA1-68CB-4897-A018-91B0810B25CBQ47327506-62A7B4D3-0A1A-4A80-8567-C3BE72824D16Q47592007-0E0C42D6-23D6-4594-8C0F-235C6BD302C9Q47629180-7807FD4F-06E4-41EA-AAA8-04FCE1C5E1D3Q47662017-DA6278F6-2F1E-4164-B161-9DDEDAE4BCAFQ47747375-CA16A436-1000-4BC3-BF5E-D14A06D13729Q47807176-05FD0246-7E61-4164-A166-5D0539EC78C4Q47810208-6C03FA78-E1FB-4A55-A685-971CC7401A92Q47851409-FDB9DABA-E8C6-4E73-9D3D-B4325B3A0324Q48148720-21DD8270-BE6C-4A7E-B974-AA41E86D5224Q48223870-0D577C82-F591-4FBA-842F-6C39CDCCB057Q48293633-AEDC06A0-7226-4DCF-913D-84A394D7CB08Q49391681-3C1969D1-EFEF-4B97-8053-99CFEA660017Q49815979-63220BE5-E2D3-4695-8861-87A3BF299403Q50133191-1E2E2BD2-1E4A-48E3-A4B1-1A678F5C5423Q50205173-7D649CED-43BD-4DFE-92FC-A00A0CF6DBD6Q52648405-5AF2C166-A8AE-4164-8883-8AD218A2A081
P2860
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pneumonitis in Patients Treate ...... rammed Death Ligand 1 Therapy.
@en
type
label
Pneumonitis in Patients Treate ...... rammed Death Ligand 1 Therapy.
@en
prefLabel
Pneumonitis in Patients Treate ...... rammed Death Ligand 1 Therapy.
@en
P2093
P2860
P50
P356
P1476
Pneumonitis in Patients Treate ...... grammed Death Ligand 1 Therapy
@en
P2093
Alexander D Guminski
Alexander M Lesokhin
Bianca Harris
Charles Leduc
Darragh Halpenny
Hira Rizvi
Jamie E Chaft
Jane Cunningham
Jarushka Naidoo
Jedd D Wolchok
P2860
P304
P356
10.1200/JCO.2016.68.2005
P407
P577
2016-09-30T00:00:00Z